| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Stem Neoplasms | 5 | 2022 | 39 | 1.920 |
Why?
|
| Glioma | 11 | 2024 | 488 | 1.470 |
Why?
|
| Chemoradiotherapy | 5 | 2024 | 103 | 1.430 |
Why?
|
| Brain Neoplasms | 19 | 2024 | 1206 | 1.390 |
Why?
|
| Medulloblastoma | 12 | 2024 | 335 | 1.120 |
Why?
|
| Cerebellar Neoplasms | 10 | 2024 | 284 | 1.080 |
Why?
|
| Astrocytoma | 4 | 2022 | 99 | 0.840 |
Why?
|
| Germinoma | 4 | 2023 | 30 | 0.610 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 1207 | 0.590 |
Why?
|
| Benzimidazoles | 2 | 2020 | 134 | 0.570 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2017 | 19 | 0.570 |
Why?
|
| Central Nervous System Neoplasms | 4 | 2023 | 195 | 0.570 |
Why?
|
| Oximes | 1 | 2017 | 50 | 0.570 |
Why?
|
| Proton Therapy | 4 | 2024 | 123 | 0.550 |
Why?
|
| Glioblastoma | 5 | 2023 | 325 | 0.540 |
Why?
|
| Imidazoles | 1 | 2017 | 194 | 0.520 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2017 | 169 | 0.510 |
Why?
|
| Cochlea | 3 | 2024 | 85 | 0.450 |
Why?
|
| Hearing Loss | 3 | 2024 | 134 | 0.420 |
Why?
|
| Biomarkers, Tumor | 7 | 2021 | 1474 | 0.420 |
Why?
|
| Mutation, Missense | 1 | 2017 | 873 | 0.410 |
Why?
|
| Child | 38 | 2024 | 24327 | 0.400 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2023 | 882 | 0.380 |
Why?
|
| Neoplastic Stem Cells | 3 | 2024 | 295 | 0.320 |
Why?
|
| Radiotherapy Dosage | 9 | 2021 | 183 | 0.310 |
Why?
|
| Photons | 2 | 2019 | 48 | 0.300 |
Why?
|
| Radiotherapy, Intensity-Modulated | 4 | 2014 | 70 | 0.290 |
Why?
|
| Child, Preschool | 22 | 2024 | 13978 | 0.280 |
Why?
|
| Cisplatin | 3 | 2024 | 234 | 0.270 |
Why?
|
| Neoplastic Syndromes, Hereditary | 2 | 2024 | 72 | 0.260 |
Why?
|
| AC133 Antigen | 2 | 2024 | 35 | 0.260 |
Why?
|
| Adolescent | 22 | 2024 | 19222 | 0.250 |
Why?
|
| Antineoplastic Agents | 4 | 2024 | 1651 | 0.240 |
Why?
|
| Radiation Injuries | 3 | 2019 | 141 | 0.240 |
Why?
|
| Neoplasm Invasiveness | 2 | 2024 | 611 | 0.240 |
Why?
|
| Humans | 48 | 2024 | 124005 | 0.230 |
Why?
|
| CD57 Antigens | 1 | 2024 | 5 | 0.230 |
Why?
|
| Formaldehyde | 1 | 2004 | 35 | 0.220 |
Why?
|
| Tissue Fixation | 1 | 2004 | 38 | 0.220 |
Why?
|
| Ethanol | 1 | 2004 | 163 | 0.200 |
Why?
|
| Oncolytic Viruses | 1 | 2023 | 73 | 0.200 |
Why?
|
| Follow-Up Studies | 6 | 2024 | 5126 | 0.200 |
Why?
|
| Oncolytic Virotherapy | 1 | 2023 | 84 | 0.200 |
Why?
|
| Rhabdoid Tumor | 2 | 2021 | 48 | 0.200 |
Why?
|
| Hydroxamic Acids | 1 | 2022 | 55 | 0.200 |
Why?
|
| Symporters | 1 | 2022 | 69 | 0.200 |
Why?
|
| Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 61 | 0.190 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2022 | 73 | 0.190 |
Why?
|
| Male | 27 | 2024 | 60908 | 0.190 |
Why?
|
| Brain | 5 | 2021 | 2977 | 0.190 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2021 | 63 | 0.190 |
Why?
|
| Pituitary Neoplasms | 2 | 2014 | 81 | 0.190 |
Why?
|
| Ependymoma | 1 | 2022 | 125 | 0.180 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2021 | 44 | 0.180 |
Why?
|
| Optic Nerve Glioma | 1 | 2021 | 21 | 0.180 |
Why?
|
| RNA, Messenger | 4 | 2014 | 2814 | 0.180 |
Why?
|
| Craniospinal Irradiation | 1 | 2021 | 58 | 0.180 |
Why?
|
| Gadolinium | 1 | 2021 | 104 | 0.180 |
Why?
|
| Neoplasms, Experimental | 1 | 2021 | 209 | 0.170 |
Why?
|
| Female | 29 | 2024 | 66186 | 0.170 |
Why?
|
| Young Adult | 7 | 2024 | 8971 | 0.170 |
Why?
|
| Bevacizumab | 1 | 2020 | 64 | 0.170 |
Why?
|
| Whole Genome Sequencing | 1 | 2021 | 277 | 0.170 |
Why?
|
| Survival Rate | 3 | 2020 | 2035 | 0.170 |
Why?
|
| Teratoma | 2 | 2018 | 122 | 0.160 |
Why?
|
| Mice | 11 | 2024 | 17578 | 0.160 |
Why?
|
| Neurofibromin 1 | 1 | 2019 | 42 | 0.160 |
Why?
|
| Ganglioglioma | 2 | 2011 | 23 | 0.160 |
Why?
|
| Valproic Acid | 1 | 2020 | 162 | 0.160 |
Why?
|
| Mice, SCID | 5 | 2023 | 565 | 0.160 |
Why?
|
| SMARCB1 Protein | 1 | 2018 | 38 | 0.150 |
Why?
|
| Enzyme Inhibitors | 1 | 2021 | 575 | 0.150 |
Why?
|
| Receptors, Cell Surface | 1 | 2021 | 469 | 0.150 |
Why?
|
| Prognosis | 4 | 2024 | 4605 | 0.150 |
Why?
|
| DNA-Binding Proteins | 2 | 2024 | 2049 | 0.150 |
Why?
|
| Capecitabine | 1 | 2017 | 16 | 0.150 |
Why?
|
| DNA Methylation | 2 | 2022 | 1003 | 0.150 |
Why?
|
| Organ Sparing Treatments | 1 | 2018 | 35 | 0.140 |
Why?
|
| Infant | 9 | 2021 | 12437 | 0.140 |
Why?
|
| Craniopharyngioma | 2 | 2014 | 32 | 0.140 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 1888 | 0.140 |
Why?
|
| Disease Models, Animal | 5 | 2023 | 4333 | 0.130 |
Why?
|
| Neoplasm Transplantation | 2 | 2016 | 371 | 0.130 |
Why?
|
| Neuroectodermal Tumors, Primitive | 2 | 2014 | 50 | 0.130 |
Why?
|
| Cell Line, Tumor | 6 | 2023 | 3327 | 0.130 |
Why?
|
| Amino Acid Substitution | 1 | 2017 | 393 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 53 | 0.130 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 723 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 6 | 2014 | 1282 | 0.120 |
Why?
|
| Protein Kinase C beta | 1 | 2014 | 21 | 0.120 |
Why?
|
| Nerve Tissue Proteins | 1 | 2021 | 1111 | 0.120 |
Why?
|
| Polycomb Repressive Complex 1 | 1 | 2014 | 29 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2021 | 833 | 0.120 |
Why?
|
| Antigens, CD1d | 1 | 2014 | 21 | 0.120 |
Why?
|
| Retrospective Studies | 10 | 2024 | 16239 | 0.110 |
Why?
|
| Animals | 12 | 2024 | 33994 | 0.110 |
Why?
|
| Supratentorial Neoplasms | 1 | 2014 | 36 | 0.110 |
Why?
|
| Indoles | 1 | 2014 | 180 | 0.110 |
Why?
|
| MutS Homolog 2 Protein | 2 | 2024 | 39 | 0.110 |
Why?
|
| MutL Protein Homolog 1 | 2 | 2024 | 53 | 0.110 |
Why?
|
| Mutation | 3 | 2024 | 5794 | 0.110 |
Why?
|
| Transplantation, Heterologous | 1 | 2014 | 252 | 0.110 |
Why?
|
| Natural Killer T-Cells | 1 | 2014 | 82 | 0.110 |
Why?
|
| DNA Mismatch Repair | 2 | 2024 | 49 | 0.110 |
Why?
|
| Cranial Irradiation | 2 | 2010 | 67 | 0.110 |
Why?
|
| Antigens, CD | 1 | 2014 | 420 | 0.100 |
Why?
|
| Meningitis, Aseptic | 1 | 2012 | 12 | 0.100 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 777 | 0.100 |
Why?
|
| Topotecan | 1 | 2012 | 48 | 0.100 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 865 | 0.100 |
Why?
|
| Glycoproteins | 1 | 2014 | 368 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2014 | 695 | 0.100 |
Why?
|
| Neoplasms, Neuroepithelial | 1 | 2012 | 12 | 0.100 |
Why?
|
| Mice, Inbred NOD | 2 | 2023 | 283 | 0.100 |
Why?
|
| Brain Edema | 1 | 2012 | 68 | 0.100 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2012 | 71 | 0.090 |
Why?
|
| Peptides | 1 | 2014 | 792 | 0.090 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2013 | 208 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2011 | 107 | 0.090 |
Why?
|
| Adult | 5 | 2024 | 29292 | 0.090 |
Why?
|
| Macrophages | 1 | 2014 | 603 | 0.090 |
Why?
|
| Chromosome Duplication | 1 | 2011 | 147 | 0.090 |
Why?
|
| Neoplasm Grading | 3 | 2019 | 272 | 0.090 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2011 | 157 | 0.080 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 1697 | 0.080 |
Why?
|
| Pituitary Diseases | 1 | 2009 | 11 | 0.080 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2009 | 32 | 0.080 |
Why?
|
| T-Lymphocytes | 1 | 2017 | 1707 | 0.080 |
Why?
|
| Radiotherapy, Conformal | 1 | 2008 | 55 | 0.070 |
Why?
|
| Disease Progression | 3 | 2021 | 2045 | 0.070 |
Why?
|
| Hamartoma Syndrome, Multiple | 1 | 2007 | 20 | 0.070 |
Why?
|
| Recurrence | 2 | 2022 | 1421 | 0.070 |
Why?
|
| Neoplasm, Residual | 2 | 2021 | 122 | 0.070 |
Why?
|
| Combined Modality Therapy | 3 | 2021 | 1223 | 0.070 |
Why?
|
| Colorectal Neoplasms | 2 | 2024 | 564 | 0.070 |
Why?
|
| Meningioma | 1 | 2008 | 117 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2014 | 1015 | 0.070 |
Why?
|
| Loss of Heterozygosity | 1 | 2006 | 125 | 0.070 |
Why?
|
| Meningeal Neoplasms | 1 | 2008 | 182 | 0.070 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 1134 | 0.060 |
Why?
|
| Vision Disorders | 2 | 2021 | 211 | 0.060 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2007 | 244 | 0.060 |
Why?
|
| Microdissection | 1 | 2004 | 12 | 0.060 |
Why?
|
| Paraffin Embedding | 1 | 2004 | 33 | 0.060 |
Why?
|
| Administration, Oral | 2 | 2017 | 681 | 0.060 |
Why?
|
| Phenylacetates | 1 | 2004 | 23 | 0.060 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 2 | 2014 | 63 | 0.050 |
Why?
|
| Lasers | 1 | 2004 | 114 | 0.050 |
Why?
|
| Phenylbutyrates | 1 | 2004 | 58 | 0.050 |
Why?
|
| DNA Mutational Analysis | 2 | 2021 | 788 | 0.050 |
Why?
|
| Prospective Studies | 3 | 2021 | 6113 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 1682 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2021 | 3543 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2007 | 667 | 0.050 |
Why?
|
| Immunohistochemistry | 3 | 2016 | 1688 | 0.050 |
Why?
|
| Liquid Biopsy | 1 | 2021 | 14 | 0.050 |
Why?
|
| Multivariate Analysis | 2 | 2017 | 1421 | 0.050 |
Why?
|
| Biphenyl Compounds | 1 | 2021 | 56 | 0.050 |
Why?
|
| Dissection | 1 | 2021 | 52 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2021 | 57 | 0.050 |
Why?
|
| Spinal Cord | 1 | 2023 | 300 | 0.050 |
Why?
|
| Morpholines | 1 | 2021 | 57 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2021 | 150 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 329 | 0.050 |
Why?
|
| Benzamides | 1 | 2021 | 106 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2021 | 92 | 0.050 |
Why?
|
| Treatment Outcome | 5 | 2017 | 12262 | 0.050 |
Why?
|
| Basal Ganglia | 1 | 2021 | 55 | 0.050 |
Why?
|
| Protons | 1 | 2021 | 92 | 0.050 |
Why?
|
| Pyridones | 1 | 2021 | 111 | 0.040 |
Why?
|
| Thalamus | 1 | 2021 | 82 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2013 | 1031 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2024 | 1317 | 0.040 |
Why?
|
| Diagnosis, Differential | 3 | 2012 | 1879 | 0.040 |
Why?
|
| Germ-Line Mutation | 1 | 2022 | 332 | 0.040 |
Why?
|
| Epigenomics | 1 | 2021 | 163 | 0.040 |
Why?
|
| Genome, Human | 1 | 2006 | 1258 | 0.040 |
Why?
|
| Salvage Therapy | 1 | 2021 | 194 | 0.040 |
Why?
|
| Infant, Newborn | 3 | 2018 | 8170 | 0.040 |
Why?
|
| Remission, Spontaneous | 1 | 2018 | 69 | 0.040 |
Why?
|
| Sarcoma, Ewing | 1 | 2019 | 106 | 0.040 |
Why?
|
| Wilms Tumor | 1 | 2019 | 112 | 0.040 |
Why?
|
| Audiometry, Pure-Tone | 1 | 2018 | 15 | 0.040 |
Why?
|
| Age Factors | 1 | 2024 | 2805 | 0.040 |
Why?
|
| Tablets | 1 | 2017 | 28 | 0.040 |
Why?
|
| Hearing | 1 | 2018 | 52 | 0.040 |
Why?
|
| Epigenesis, Genetic | 1 | 2022 | 674 | 0.040 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2006 | 2625 | 0.040 |
Why?
|
| Radiation Tolerance | 1 | 2018 | 46 | 0.040 |
Why?
|
| Contrast Media | 1 | 2021 | 470 | 0.040 |
Why?
|
| Cell Movement | 1 | 2021 | 831 | 0.040 |
Why?
|
| Radiation Dosage | 1 | 2018 | 135 | 0.040 |
Why?
|
| Neoplasm Staging | 2 | 2014 | 1233 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2018 | 133 | 0.030 |
Why?
|
| Osteosarcoma | 1 | 2019 | 252 | 0.030 |
Why?
|
| Rhabdomyosarcoma | 1 | 2019 | 191 | 0.030 |
Why?
|
| SEER Program | 1 | 2017 | 202 | 0.030 |
Why?
|
| Incidence | 1 | 2024 | 3134 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 942 | 0.030 |
Why?
|
| Visual Acuity | 1 | 2021 | 824 | 0.030 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 270 | 0.030 |
Why?
|
| Heterografts | 1 | 2016 | 171 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 859 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 3413 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 2137 | 0.030 |
Why?
|
| Aldehyde Oxidoreductases | 1 | 2014 | 19 | 0.030 |
Why?
|
| Risk Factors | 2 | 2021 | 10239 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2019 | 1084 | 0.030 |
Why?
|
| Eukaryotic Initiation Factor-4G | 1 | 2014 | 41 | 0.030 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2014 | 22 | 0.030 |
Why?
|
| Neurosurgical Procedures | 1 | 2017 | 305 | 0.030 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2014 | 37 | 0.030 |
Why?
|
| Neuroblastoma | 1 | 2019 | 518 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2021 | 2284 | 0.030 |
Why?
|
| Adenoviridae | 1 | 2017 | 605 | 0.030 |
Why?
|
| Time Factors | 2 | 2021 | 6278 | 0.030 |
Why?
|
| Herpesvirus 4, Human | 1 | 2017 | 676 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 1 | 2014 | 258 | 0.030 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 152 | 0.030 |
Why?
|
| Receptor, ErbB-2 | 1 | 2017 | 514 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2017 | 481 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 663 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2014 | 708 | 0.030 |
Why?
|
| Carboplatin | 1 | 2013 | 76 | 0.030 |
Why?
|
| Endocrine System Diseases | 1 | 2013 | 39 | 0.030 |
Why?
|
| Cell Cycle | 2 | 2006 | 608 | 0.030 |
Why?
|
| Infusions, Intraventricular | 1 | 2012 | 12 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2013 | 140 | 0.030 |
Why?
|
| Affective Symptoms | 1 | 2013 | 58 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2014 | 659 | 0.030 |
Why?
|
| Vincristine | 1 | 2013 | 191 | 0.020 |
Why?
|
| Medical Records | 1 | 2013 | 189 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2014 | 501 | 0.020 |
Why?
|
| Maximum Tolerated Dose | 1 | 2012 | 158 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1490 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2014 | 352 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2014 | 481 | 0.020 |
Why?
|
| Genomics | 1 | 2019 | 1484 | 0.020 |
Why?
|
| Central Nervous System | 1 | 2013 | 251 | 0.020 |
Why?
|
| TNF Receptor-Associated Factor 2 | 1 | 2011 | 8 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2021 | 3426 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2013 | 762 | 0.020 |
Why?
|
| Base Sequence | 2 | 2006 | 3087 | 0.020 |
Why?
|
| Dexamethasone | 1 | 2012 | 273 | 0.020 |
Why?
|
| Survivors | 1 | 2013 | 322 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 1613 | 0.020 |
Why?
|
| Amifostine | 1 | 2010 | 14 | 0.020 |
Why?
|
| Organs at Risk | 1 | 2010 | 24 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1746 | 0.020 |
Why?
|
| Radiography | 1 | 2012 | 823 | 0.020 |
Why?
|
| Sella Turcica | 1 | 2009 | 4 | 0.020 |
Why?
|
| Diabetes Insipidus, Neurogenic | 1 | 2009 | 4 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2010 | 356 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2010 | 338 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2013 | 373 | 0.020 |
Why?
|
| Pituitary Gland | 1 | 2009 | 82 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2013 | 551 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2014 | 1266 | 0.020 |
Why?
|
| Cognition | 1 | 2013 | 707 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2009 | 171 | 0.020 |
Why?
|
| Encephalitis | 1 | 2009 | 109 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2010 | 1007 | 0.020 |
Why?
|
| Anaplasia | 1 | 2007 | 6 | 0.020 |
Why?
|
| Glyceraldehyde-3-Phosphate Dehydrogenases | 1 | 2007 | 23 | 0.020 |
Why?
|
| Isomerism | 1 | 2007 | 31 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2007 | 46 | 0.020 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2006 | 23 | 0.020 |
Why?
|
| Gene Amplification | 1 | 2006 | 228 | 0.020 |
Why?
|
| ErbB Receptors | 1 | 2006 | 284 | 0.020 |
Why?
|
| Texas | 1 | 2013 | 3580 | 0.010 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2004 | 16 | 0.010 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2004 | 124 | 0.010 |
Why?
|
| DNA Primers | 1 | 2005 | 656 | 0.010 |
Why?
|
| G1 Phase | 1 | 2004 | 67 | 0.010 |
Why?
|
| Middle Aged | 2 | 2017 | 26569 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 182 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 776 | 0.010 |
Why?
|
| United States | 1 | 2017 | 10853 | 0.010 |
Why?
|
| Alleles | 1 | 2006 | 1615 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2004 | 1100 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2004 | 795 | 0.010 |
Why?
|
| Genotype | 1 | 2006 | 2552 | 0.010 |
Why?
|
| Histones | 1 | 2004 | 528 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 19516 | 0.010 |
Why?
|
| Apoptosis | 1 | 2004 | 1777 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 1889 | 0.010 |
Why?
|
| Neurons | 1 | 2004 | 1957 | 0.010 |
Why?
|